Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine carcinoma of the skin mediated by the integration of Merkel cell polyomavirus (MCPyV) and expression of viral T antigens or by ultraviolet induced damage to the tumor genome from excessive sunlight exposure. An increasing number of deep sequencing studies of MCC have identified significant differences between the number and types of point mutations, copy number alterations, and structural variants between virus-positive and virus-negative tumors. In this study, we assembled a cohort of 71 MCC patients and performed deep sequencing with OncoPanel, a next-generation sequencing assay targeting over 400 cancer-associated genes. To improve the accuracy and sensitivity for virus detection compared to traditional PCR and IHC methods, we developed a hybrid capture baitset against the entire MCPyV genome. The viral baitset identified integration junctions in the tumor genome and generated assemblies that strongly support a model of a hybrid, virus-host, circular DNA intermediate during integration that promotes focal amplification of host DNA. Using the clear delineation between virus-positive and virus-negative tumors from this method, we identified recurrent somatic alterations common across MCC and alterations specific to each class of tumor, associated with differences in overall survival. Comparing the molecular and clinical data from these patients revealed a surprising association of immunosuppression with virus-negative MCC and significantly shortened overall survival. These results demonstrate the value of high-confidence virus detection for identifying clinically important features in MCC that impact patient outcome. March 23, 2019 not initiating event in virus-positive MCC oncogenesis. MCPyV infects most people, typically at an early age, and results in an asymptomatic and lifelong infection indicated by the presence of antibodies to the viral coat protein VP1 (3, 4). Although MCPyV DNA can be readily detected on the skin, the cell types where the virus replicates in vivo have not been determined (5).
Introduction
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine carcinoma of the skin.
Risk factors for developing MCC include advanced age, light skin color with excessive sunlight exposure, and a variety of immunocompromised conditions (1) . In 2008, Merkel cell polyomavirus (MCPyV) was first detected by Southern blot in some but not all MCC tumors with integration of viral DNA occurring at several different chromosomal sites. Importantly, an identical clonal integration pattern was detected in one tumor and corresponding metastatic lymph node (2) . This important insight implied that integration of the viral DNA was an early if between virus-positive MCC and virus-negative MCC. Several recent studies have hinted at differences between virus-positive MCC and virus-negative MCC in presentation, age, and response to immunotherapy (9) (10) (11) (12) (13) (14) (15) . However, current techniques for determining viral status have yielded either inaccurate or ambiguous results. Although WGS provides much more genetic information on the tumor and viral genome compared to targeted approaches, it remains impractical for clinical evaluation of MCC.
The most common methods for detection of MCPyV in MCC include PCR amplification of MCPyV DNA from DNA isolated from MCC tumors or immunohistochemistry (IHC) staining for MCPyV LT using monoclonal antibodies CM2B4 and Ab3 (16, 17) . However, both PCR and IHC have been shown to be unreliable in distinguishing between virus-positive from virus-negative MCC. For example, a recent study of 282 cases of MCC evaluated virus-positivity by IHC with CM2B4 and Ab3 and PCR with a previously validated primer set (18) . Notably, there was concordance for all three assays in only 167 of 282 (59.2%) cases with an additional 62 cases positive for 2 of the 3 tests. The remaining 53 (18.8%) were positive for 1 test or none. This study assigned the MCC to be virus-positive if 2 or 3 tests were positive; therefore, detection of viral DNA by PCR alone was not sufficient for a tumor to be called virus-positive MCC.
Furthermore, because of the sensitivity of PCR in detecting DNA, a lower limit of 0.01 copy of MCPyV DNA per tumor cell was called virus-positive MCC. Tumors containing < 0.01 viral copies/cell were called virus-negative. A different study using RNA-FISH to detect mRNA specific for MCPyV LT and ST found this method to be as sensitive as qPCR when using two primer sets and the viral copy number was set to > 0.004/cell (19) . The AMERCK test detects circulating antibodies against the MCPyV ST (20) . The sensitivity of this test is low for detection of virus-positive MCC but, when positive, can be used as a biomarker for disease status (20) .
The high somatic mutation burden in virus-negative MCC is predicted to result to yield more tumor neoantigens than melanomas or non-small cell lung cancers (median of 173, 65, and 111 neoantigens/sample, respectively) (21) (22) . As observed for other tumor types, the high March 23, 2019 neoantigen burden in virus-negative MCC corresponds with a higher degree of tumor infiltrating lymphocytes in some tumors, but these tumors also express PD-L1 rendering these lymphocytes ineffective (7) . Despite the numerous observed differences in mutation rate and number of predicted neoantigens, both virus-positive MCC and virus-negative MCC tumors have shown high response rates to PD-L1 and PD1 checkpoint blockade therapy (14, 15) .
For further advancements to be made in understanding MCC, especially for patients not responsive to current therapies, clear and accurate determination of the MCPyV virus status and actionable variants in these tumors are required. In this study, we developed a viral hybrid capture next-generation sequencing (NGS) method to detect the presence of integrated MCPyV DNA in FFPE clinical specimens. This approach was combined with targeted sequencing of several hundred cancer-related genes to assess oncogenic changes in the tumor genome. We compared this viral hybrid capture approach to PCR detection of viral DNA, IHC for detection of MCPyV LT, and synoptic assessment of MCC pathology.
Results

Summary of patient cohort
A total of 71 patients diagnosed with MCC were included in this study ( Table 1 ). The median (95% CI) follow-up duration from initial diagnosis of MCC was 47 (95% CI: 38 -60) months based on inverse Kaplan-Meier estimation. Overall, 69 enrolled patients were white and two were black. Forty (56%) patients were male. The median age was 70 years (range: <50 to 93). The initial site of MCC presentation was in the head and neck (27%), upper extremity (20%), lower extremity (21%) and trunk (32%). The seventh edition TNM staging system of the American Joint Committee on Cancer (AJCC) was used to classify the initial presentation of MCC with 27% presenting at stage I, 14% Stage II, 42% Stage III, and 17% Stage IV.
Somatic Variant Analysis of Targeted Sequencing
March 23, 2019 6 All 71 patients underwent OncoPanel analysis (23) . Genomic studies were performed using DNA isolated from tumors obtained at the time of initial diagnosis (50) or upon relapse (21) . The total number of mutations ranged from 0 to 73 corresponding to a Tumor Mutational Burden (TMB; mutations/megabase) from 0 to 38.89 with four cases containing no detectable mutations ( Figure 1A , Table S1 ). From this mutation data, patients were binned into TMB-high (>=20), TMB-intermediate (>6<20), and TMB-low (<=6) . A limited set of mutation signatures could be identified (see Methods). The UV mutational signature (Signature 7) was detected in 24 cases, corresponding to the TMB-high patients (24) . Additional mutational signatures identified included Aging (Signature 1; 3 cases), APOBEC (Signatures 2 & 13; 4 cases with 3 that also had an UV signature), and Signature 5 (one case) ( Figure 1A , Table S1 ). TMB had some correlation with the number of copy number altered genes ( Figure 1B ). Several genes including RB1, TP53, KMT2D, NOTCH1, NOTCH2, and FAT1 were highly enriched for missense and truncating mutations ( Figure 1C , Figure S1 ). Single and dinucleotide substitutions in RB1 and TP53 revealed that most were likely mediated by UV damage (CC>TT, C>T; Figure   1D ).
Copy number variants (CNVs) were examined individually as well against each other and other likely functional somatic changes for significant co-occurrence or mutual exclusivity (Table S2 ). Clusters of significantly co-occurrent CNVs were determined via network analysis ( Figure 2A , Table S3 ). From these analyses, two chromosomal regions were found to be altered in more than 36% of cases ( Figure 2B & C). Chromosome 10 (cluster 14) had frequent copy number loss with many tumors showing complete loss of the entire chromosome ( Figure 2B ) (25) . Some cancer-relevant genes on chromosome 10 include PTEN and SUFU, negative regulators of PI3K and Hedgehog signaling respectively, with deletions reported in prior studies of MCC (25, 26) . A region of Chr1q (cluster 13) was amplified in 28 cases. This region includes MDM4 (also known as MDMX), whose protein product cooperates with MDM2 to promote the ubiquitination and subsequent degradation of p53 ( Figure 2B) (27, 28) . In addition, we observed March 23, 2019 a focal amplification of MYCL in Chr1p (cluster 4), which was reported in an earlier study of MCC (29) .
The CNV clusters were observed at nearly equal frequencies in both TMB-high and TMB-low cases ( Figure 2B & C) . Many of the other CNV clusters were strongly associated with UV signature and high TMB ( Figure 2C ). However, cluster 5 that included an amplification of chromosome 6 was more than twice as frequent in TMB-low tumors than TMB-high tumors ( Figure 2C ). Interestingly, 35% of metastatic tumors carried cluster 5 and all but one of these metastatic tumors were TMB-low MCC. Furthermore, CNV cluster 5 was 2.5 times more frequent in TMB-low (22.2%) than TMB-high (8.7%) tumors in primary tumors. Both TMB-low and TMB-high patients with amplification of CNV cluster 5 had significantly improved overall survival compared to wild-type carrying patients that had a median survival time of 41.65 months (p=0.0027). Restricting this analysis to only primary tumors, revealed that there were no deaths at the time of this study in patients carrying this amplification (p<0.001) ( Figure 2D & E).
The recurrent copy number events on chromosomes 1 and 10 were compared within TCGA for similarities to other tumor types ( Figure 2F -G). This analysis revealed that the chromosome 1 amplification was also frequently observed in ovarian, breast, and bladder cancers; whereas, the chromosome 10 loss was most frequently seen in prostate cancer.
Analysis of Viral Sequences in Tumors
Of the 71 tumors analyzed by Oncopanel, 48 were re-analyzed by Oncopanel (Profile/OncoPanel version 3, POPv3) combined with a hybrid-capture probe bait set targeting the entire genome of MCPyV (VB2). For the 48 cases, the number of MCPyV reads ranged from 0-21,095,751 with only a single case having zero MCPyV reads ( Figure 3A ). In total, 28 cases had substantial reads (>6,800) mapping to the MCPyV genome that also supported integration of the virus into the host genome. For the remaining 20 cases without evidence for integration, the number of viral reads ranged from 0 to 971. Generally, these cases had reads that covered March 23, 2019 8 less than 10% of the viral genome with the normalized coverage less than two logs compared to samples with evidence for virus integration (Figure 3B & C, Table S3 ). Concordantly, the viral reads from most of these cases were unable to be assembled into larger viral contigs. Two cases, MCC011 and MCC015, had 212 and 177 MCPyV reads that could be assembled into nine and five contigs each smaller than 761 base pairs, respectively. Case MCC007 had the most reads of any likely virus-negative sample and could be assembled into a single 5343 bp contig. However, analysis of the point and deletion variants in these aforementioned viral contigs revealed that they were identical to the virus sequence from patient MCC037 indicating that the viral reads resulted from low level contamination (<0.005% of MCC037 MCPyV reads were detected in other samples).
For the 28 cases with evidence for integration of the viral DNA into the tumor, the number of reads mapping to the viral genome ranged from 6,824-21,095,751 (Median: 28,726).
Consistent with previous reports, the integrated viral genome had undergone extensive mutagenesis with large deletions (>100 bp) particularly in the 3' half of LT ( Figure 4 ). In 10 cases, approximately half of the total viral genome was deleted, 6 cases had approximately 25% of the viral genome deleted, while 12 cases had sequences corresponding to the entire or nearly complete genome ( Figure 3C & 4) . In all but one of the cases with a nearly complete coverage of the viral genome, there was a clonal point mutation which inserted a premature stop codon in LT resulting in truncated proteins between 208 and 771 amino acids ( Figure 5A ).
In a single case (MCC054), LT was truncated by a 5bp deletion resulting in a frame shift putting a premature stop codon in frame. In all cases, the non-coding control region, the N-terminal 208 residues of LT, and an intact ST region of the viral genome were conserved. Beyond indels and nonsense mutations, LT also carried numerous clonal missense mutations ( Figure 5A ). In stark contrast, ST only had missense mutations at three residues, and the amino acid change A20S is consistent with a previously observed MCPyV strain difference (GenBank identical protein accession number: ACI25295.1). The other missense mutations occurred clonally at H41Y and March 23, 2019 N100S once in the entire cohort ( Figure 5B ). Neither of these mutations are present in any of the ST sequences in GenBank.
The integration sites were mapped using the oncovirus tools suite (https://github.com/gstarrett/oncovirus_tools) ( Figure 6A , Table 2 ). As previously reported, integrations primarily fell into two categories: either those that appear as a single integration event or as two events separated by >10 kilobases (kb) (8) . Interestingly, two cases had integration events in non-identical but overlapping sites in chromosome 1 ( Figure 6B ). These represent the first reported cases of recurrent viral integration sites or hotspots in MCC.
Because of the limited number of capture targets of the OncoPanel platform, determining the extent of virus-mediated amplifications expected in the tumor genome was not possible.
However, using the normalized viral coverage, the estimated number of viral genome copies ranged between 1 and 1881 copies (median: 7, interquartile range (IQR): 4-13) ( Table 2) .
Additionally, based on previous observations, we can infer that the regions between viral integration sites were amplified (8) . When annotating these regions, we observed that they frequently contain enhancer regions that may contribute to oncogenesis as seen in HPVassociated tumors (30) . Patient MCC026 had integrations on chromosomes 9, 16, and 18, all of which had integration sites separated by 107.5 and 129.9 kbp. Using automated computational methods, we could not confidently determine an integration site for case MCC037 with the highest viral genome copy number in this study. Manually interrogating the human sequence hits from the assembly revealed that it matched a tandem repeat sequence flanked by MLT1H2 ERVL-MaLR elements. Based on the estimated copy number and the assembly graph, the viral component of this fusion DNA structure is likely larger than 10 Mbp ( Figure S4 ).
With the high depth of coverage facilitated by the targeted NGS method, high resolution assemblies for the integrated virus were generated. Many integrations that appeared as a single Figure 6E , Figure S4 ).
To address a possible mechanism for integration, we looked for microhomology between the human and MCPyV genomes at fusion junctions. We found significant enrichment for 4, 5, and 7 bp sequence microhomology at the site of integration compared to randomly selected sites in the human and MCPyV genomes ( Figure 6F ). There was no significant increase in overall homology between MCPyV and human DNA at integration sites versus randomly selected sites. Patient MCC027 had the integration site with the longest stretch of homology and MCC041 had both the integration site with the greatest overall homology on its 3' end and lowest homology with no microhomology greater than 1bp on its 5' end ( Figure 6G ).
Additionally, we annotated integration sites for proximity to repeat elements, including LINES, SINES, LTR retrotransposons, and simple repeats in the human genome. No type of repeat element was significantly enriched, but all integration sites were within 1.5kb of a repeat element and there was a trend towards integrations near LTR retrotransposons and lowcomplexity regions ( Figure 6H ).
Distinguishing virus-positive MCC from virus-negative MCC using somatic variants in comparison to Immunohistochemistry and PCR
Given the striking differences in the number of mutations and mutational signature we observed in the VB2 dataset that strongly correlated with virus integration, we compared the data from the OncoPanel and POPv3VB2 datasets to determine the viral status of all 71 tumors March 23, 2019 studied ( Table 3) . From the OncoPanel sequencing, we identified off-target reads for MCPyV in a total of 18/71 cases, ranging from 1 to 194 reads total. When compared to the VB2 data, there was a rough correlation between the number of off-target reads and the number of MCPyV reads in the VB2 dataset. There were 8 samples with MCPyV reads in the OncoPanel dataset that were not also analyzed by VB2. None of these 8 cases have any evidence for a UV mutational signature.
We assessed the total number of mutations, TMB, UV signature, and detection of MCPyV (Table 3 ). In addition, DNA was tested by PCR with 5 primer sets for 15 cases. In 9 virus-positive MCC cases, all returned positive results with 2 to 5 primer sets ( Table 3 ). For 6 virus-negative cases, PCR was negative for 5 primer sets and one was positive with one primer set. Interestingly, the virus-negative MCC (MCC007) with one PCR March 23, 2019 primer set positive also ranked at the TMB borderline (9.58) between virus-negative and viruspositive and did not score as having a UV mutational signature; rather, the majority of mutations were classified as APOBEC-associated.
A synoptic review of dermatopathology was available for 19 cases (Table S4) 
Statistical comparison of clinical and molecular characteristics
Overall, 28 patients remained disease free after initial therapy and 43 developed one or more relapses or persisted as stage IV. According to the biopsy type and first recurrence status, patients could be grouped into primary biopsy with no further recurrence (N=30), primary biopsy with further recurrence (N=22), and recurrence biopsy (N=19). For all samples annotated with recurrence, the first recurrence occurred before the biopsy was obtained. Regardless of the biopsy type, patients were grouped into no relapse (N=30) and relapse (N=41). Figure 7A , Table 5 ). Virus-negative MCC was present in three patients with solid organ transplantation, three with auto-immune disease including myasthenia gravis, rheumatoid arthritis, or granulomatosis with polyangiitis, one with monoclonal gammopathy of undetermined significance (MGUS) , and another with Waldenstrom's macroglubulinemia. In contrast, virus-positive MCC was identified in a patient with mantle zone lymphoma having been treated with Rituximab for 3 years and another with somatic mutations in NF1 and GATA2 (33) . The median OS for patients with immunosuppression was 17.5 months (95% CI: 5.6-24.4) months, significantly shorter than patients without immunosuppression (48.5 months, 95% CI: 35.4-113.3, p<0.01) ( Figure 7B , Table 5 ).
Discussion
We undertook this study to develop an assay to more accurately distinguish between viruspositive and virus-negative MCC. We built upon an NGS platform that has been instituted as a routine part of clinical care at the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital. The viral hybrid capture assay, VB2, acquired a high number of MCPyV reads for many samples. Importantly, evidence for specific integration was associated with all cases with a high number of reads (>6,000). Spurious MCPyV reads were also detected in 19 of 20 MCC cases that were deemed to be virus-negative by TMB and UV mutations. There was no evidence for integration in these cases rather these reads could be traced to be extremely low level contamination from MCC037 during library preparation or sequencing. In Integration sites were observed on 12 different chromosomes with the most occurring on chromosome 5. In addition, two fully overlapping integration sites from two different tumors were March 23, 2019 observed on chromosome 1 separated by only 10-20kb. Based on the clonality of deletions and point mutations in the MCPyV genome, these events most likely occurred before or during integration as was similarly determined from another study on MCC cell lines (34) . From previous publications, we can infer that these integration sites likely have amplified adjacent regions of the host genome in a tandem head-to-tail conformation (8) . These integration sites frequently are within 50 kb of each other and flank or fully contain enhancer regions of the human genome. These observations are consistent with reports of HPV integration in cervical and head and neck cancers as well as cell lines (35) . Particularly, HPV integration events can amplify enhancer regions to high copy number creating super enhancers that can drive expression of adjacent genes and tumor cell survival. This likely represents another important mechanism beyond the expression of the viral tumor antigen in promoting tumorigenesis.
A recurrent amplification of chromosome 6 has previously been observed for MCC; however, this observation predated the discovery of MCPyV and was not associated with morphology or outcome (36) . In other cancers, such as basal cell carcinoma and ovarian cancer, this amplification is typically associated with worse outcome (36) . Although the chromosome 6 amplification in this study was significantly associated with better overall survival, it was also more frequent in metastasis. This amplification co-occurring with MCPyV may represent a less fatal, but more metastatic subtype of MCC. Additionally, this result could be impacted by the immunotherapy administered to the patients with metastatic MCC.
Unexpectedly, we observed that 8 of 10 cases with immunosuppression were virusnegative MCC. While it was recognized in the early 1990s that individuals with hematologic malignancies that developed MCC had a poor prognosis (37), it was not until 1997 when a direct link between immunosuppression and MCC was postulated (38) . At that time, a correlation was noted between medically induced immunosuppression with azathioprine and cyclosporine and the development and rapid spread of MCC. Early reports highlighted a prolonged period of immunosuppression prior to MCC development. The search for a viral pathogen in MCC was initiated because of reports linking MCC with immunosuppression and with HIV-1/AIDS (2) .
In the present report, three solid organ transplant recipients, three with chronic autoimmune diseases, and two with hematologic malignancies developed virus-negative MCC. The risk for developing MCC is increased in patients with chronic inflammatory disorders such as rheumatoid arthritis or medically induced immunosuppression for solid organ transplantation (38) (39) (40) (41) . Skin cancers account for 40-50% of all posttransplant malignancies with squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) comprising 90-95% of these skin cancers (42) . Importantly, some therapeutics used in organ transplantation increase risk for developing skin cancers. Azathioprine can sensitize cells to UV-induced damage through the incorporation of a metabolite into DNA that generates reactive oxygen species upon exposure to UV light (43) . In patients with rheumatoid arthritis, methotrexate and anti-TNF drugs were associated with an increased risk of non-melanoma skin cancer (44) . The increased risk for skin cancers in organ transplant recipients and rheumatoid arthritis is associated with UV-light induced mutagenesis for SCC and BCC. Therefore, the increased risk for UV-induced skin cancers may also extend to virus-negative MCC. While genomic sequencing has revealed that virus-negative MCC has evidence for a high degree of UV damage, this does not exclude a role for UV exposure in the development of virus-positive MCC. The relative lack of UV damaged DNA in virus-positive MCC indicates that the etiologies are clearly different, suggesting that the precursor to virus-negative MCC was a recipient of life-long intense UV exposure while the virus-positive MCC were not exposed to sunlight for the same degree or for as long. It was reported that the early promoter of MCPyV responds to UV exposure and that levels of ST mRNA increased in UV exposed skin from a healthy human volunteer (46) . Transient UV exposure could affect the immune response to virus-negative and virus-positive MCC etiology. The effect of UV radiation in the pathogenesis of MCC has been suggested to be more likely a result of immune modulation than direct effects on DNA itself (47) .
Materials and Methods
Sample collection
DNA was isolated from FFPE sections of MCC tumors corresponding to the 71 individuals summarized in Table 1 . In addition, FFPE sections were sectioned for immunohistochemistry with antibodies CM2B4 and Ab3 (17) . Sections stained with hematoxylin and eosin were evaluated by synoptic review (32) .
Nucleic acid isolation, library preparation and sequencing
Purified DNA was quantified using a Quant-iT PicoGreen dsDNA assay (ThermoFisher). 
Sequence alignment and somatic variant calling
Pooled samples were de-multiplexed and sorted using Illumina's bcl2fastq software (v2.17). Reads were aligned to the reference sequence b37 edition from the Human Genome Reference Consortium as well as viral genomes targeted by the Virus Capture Baitset v2 using bwa mem (http://bio-bwa.sourceforge.net/bwa.shtml) (48) . The viral genomes and human genome were combined into one alignment reference so reads could map to the closest matching reference sequence.
Duplicate reads were identified using unique molecular indices (UMIs) and marked using the Picard tools. The alignments were further refined using the Genome Analysis Toolkit (GATK) for localized realignment around indel sites and base quality score recalibration (49, 50) .
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Mutation analysis for single nucleotide variants (SNV) was performed using MuTect v1.1.4 (CEPH control was used as the "project normal") and annotated by Variant Effect
Predictor v 79 (VEP) (51, 52) . We used the SomaticIndelDetector tool that is part of the GATK for indel calling. After initial identification of SNVs and indels by MuTect and GATK respectively, the variants were annotated using OncoAnnotate to determine what genes were impacted and their effect on the amino acid sequence. OncoAnnotate also applied additional filters using the Exome Sequencing Project (ESP) and gnomAD datasets to flag common SNPs.
Variants that affect protein coding regions underwent further filtering/classification based on frequency in the gnomAD, ESP, and COSMIC (version 80) databases. If the frequency of the variant was less than or equal to 1% in all gnomAD and ESP populations, the variant was flagged as "REVIEW_REQUIRED". If the frequency of the variant was greater than 1% and less than or equal to 10% in all gnomAD and ESP populations and present in "COSMIC" database at least 2 times, the variant was flagged as "REVIEW_REQUIRED". If the frequency of the variant was between 1% and less than or equal to 10% in all gnomAD and ESP populations and not present in "COSMIC" database at least 2 times, the variant is flagged as "NO_REVIEW_GERMLINE_FILTER". If the frequency of the variant was greater than 10% in any gnomAD and ESP populations, the variant was flagged as "NO_REVIEW_GERMLINE_FILTER". Variants with a frequency greater than 10% in any gnomAD or ESP population were considered to be a common SNP irrespective of presence in the COSMIC database.
Variants in the viral genomes were called using samtools mpileup and bcftools from the aligned bam files. Called variants were filtered to have a minimum coverage of 5 reads and minimum allele frequency of 1% of total reads covering that base in a single sample. Variants were annotated based on the NC_010277.2 reference sequence in GenBank using SnpEff (PMID: 22728672).
Recurrent copy number analysis
Copy number variant calling was performed using a combination of VisCap Cancer and CNVkit as previously described (23) (53) . All resulting gene copy number variants from all patients were compared against each other with UV status and significant mutual exclusivity/cooccurrence was calculated using Fisher's exact test corrected by FDR for multiple comparisons in the R statistical environment. Using the network and iGraphs packages the significantly cooccurrent variants were clustered into networks. The genes belonging to each distinct network cluster with more than 5 member genes were then labeled and extracted. Using these gene lists as cluster definitions each patient was evaluated for presence or absence of each CNV cluster.
Presence of a CNV cluster was determined if more than 50% of the member genes of that cluster were modified in the same patient. Code is available from https://github.com/gstarrett/oncovirus_tools.
Viral integration analysis
A custom perl script was written to extract, assemble, annotate, and visualize viral reads and determine viral integration sites. Viral reads and their mates were first identified and extracted by those that have at least one mate map to the viral genome. Additional reads containing viral sequence were identified by a bloom filter constructed of unique, overlapping 31bp k-mers of the MCPyV genome (54) . The human genome positions for any read with a mate mapping to the viral genome were output into a bed file and the orientation of viral and human pairs was stored to accurately deconvolute overlapping integration sites. This bed file was then merged down into overlapping ranges based on orientation counting the number of reads overlapping that range. Skewdness in coverage of integration junctions was calculated by the difference in the fraction of virus-host read pairs overlapping the first and second halves of the aforementioned ranges. This skewdness value was used to determine the orientation of the viral-host junction (i.e. positive values, junction is on the 3' end of the range; negative values, junction is on the 5' end of the range), which was validated from the results of de novo assembly. Integrated viral genomes were assembled from extracted reads using SPAdes with default parameters (55) . The assembly graphs from SPAdes were annotated using blastn against hg19 and the MCPyV reference genome with an e-value cutoff of 1x10 -10 . Annotated assembly graphs were visualized using the ggraph R package. Code is available from https://github.com/gstarrett/oncovirus_tools. Integrations sites confirmed by reference guided alignment and assembly data were analyzed for stretches of microhomology between the human and viral genomes by selecting 10bp upstream and downstream of the integration junction on the viral and human genomes.
Within these sequences stretches of identical sequence at the same position longer than two base pairs were counted. Overall homology between the sequences was calculated by Levenshtein distance (). Three integration junctions with indeterminate DNA sequence ranging from 1-25bp inserted between viral and human DNA were excluded from analysis. Expected microhomology was calculated by randomly selecting 1000 20bp pairs of non-N containing sequence from the human and MCPyV genomes.
Integration site proximity to repeat elements were determined using bedtools closest and repeatmasker annotations acquired from the UCSC genome browser (56) . Expected frequency of integration near repeat elements were determined by randomly selecting 1000 sites in the human genome. Sites within 2kb of a repeat element were counted as close proximity.
Statistics
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Cox regression model is built to investigate the association between virus status and overall
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